FDA News Digest
September 24, 2007
__________________________________________
IN
THIS WEEK'S ISSUE
»
News
-- Phasing Out CFCs in Metered-Dose Epinephrine Inhalers Proposed
-- Genetic Test Cleared to Show Sensitivity to Blood-Thinner Warfarin
-- Rapid Screening Test for Harmful Bacteria in Blood Platelets OK'd
» Safety Alerts/Recalls
» Upcoming
Public Meetings
» Consumer Health Information __________________________________________
NEWS
Phasing Out CFCs in Metered-Dose Epinephrine
Inhalers
Proposed
FDA is proposing a rule that would phase out the use of
ozone-depleting chlorofluorocarbons (CFCs) in metered-dose epinephrine
inhalers, which are used for temporary relief of mild asthma. Under the rule,
epinephrine metered-dose inhalers containing CFCs would be removed from the
market by the end of
2010.
Genetic Test Cleared to Show Sensitivity
to
Blood-Thinner Warfarin
FDA has cleared for marketing a new genetic test that
can help doctors gauge whether a patient may be sensitive to the blood-thinning
drug warfarin (Coumadin), which is used to prevent clots in blood
vessels.
Rapid Screening Test for Harmful Bacteria in
Blood Platelets
OK'd
FDA has approved the Platelet Pan Genera Detection
system, the first rapid test to detect bacterial contamination in blood
platelets before transfusion. Platelets are used to prevent or treat bleeding in
patients following, for example, major trauma or surgery.
Patients who receive platelets contaminated with bacteria are at risk of
a potentially life-threatening infection called blood
poisoning.
To view an archive of past FDA news releases, go to
To access the RSS feed of FDA news releases, go
to
http://www.fda.gov/bbs/topics/news/rssPress.xml.
[What is an RSS feed? See http://www.fda.gov/bbs/topics/news/newsfeeds.html.]
___________________________________________
SAFETY
ALERTS/RECALLS
Safety
Alerts:
FDA
is warning consumers not to use
--